376 related articles for article (PubMed ID: 23330781)
21. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
22. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
23. Beyond BRAF: where next for melanoma therapy?
Fedorenko IV; Gibney GT; Sondak VK; Smalley KS
Br J Cancer; 2015 Jan; 112(2):217-26. PubMed ID: 25180764
[TBL] [Abstract][Full Text] [Related]
24. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
27. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
[TBL] [Abstract][Full Text] [Related]
28. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
29. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
30. A review of binimetinib for the treatment of mutant cutaneous melanoma.
Koelblinger P; Dornbierer J; Dummer R
Future Oncol; 2017 Aug; 13(20):1755-1766. PubMed ID: 28587477
[TBL] [Abstract][Full Text] [Related]
31. The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.
Lin R; Xia S; Shan C; Chen D; Liu Y; Gao X; Wang M; Kang HB; Pan Y; Liu S; Chung YR; Abdel-Wahab O; Merghoub T; Rossi M; Kudchadkar RR; Lawson DH; Khuri FR; Lonial S; Chen J
Mol Cell; 2018 Mar; 69(6):923-937.e8. PubMed ID: 29547721
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapies for cutaneous melanoma.
Kee D; McArthur G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
[TBL] [Abstract][Full Text] [Related]
33. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
34. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
35. [Translational research and diagnostics of melanoma].
Rüschoff J; Kleinschmidt M; Middel P
Pathologe; 2012 Nov; 33 Suppl 2():291-5. PubMed ID: 22968732
[TBL] [Abstract][Full Text] [Related]
36. NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib.
Parekh V; Sobanko J; Miller CJ; Karakousis G; Xu W; Letrero R; Elenitsas R; Xu X; Elder DE; Amaravadi R; Schuchter LM; Nathanson KL; Wilson MA; Chu EY
J Cutan Pathol; 2019 Mar; 46(3):190-194. PubMed ID: 30552700
[TBL] [Abstract][Full Text] [Related]
37. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
38. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
[TBL] [Abstract][Full Text] [Related]
39. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
40. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
